Holen Sie sich die Stockscreener-App
0.00
100.00%
-9.71
Handel nachbörslich:
9.75
9.75
+
Schlusskurs vom Vortag:
$9.71
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$39.28M
Einnahmen:
$147.75M
Nettoeinkommen (Verlust:
$-284.23M
KGV:
0.00
EPS:
-2.93
Netto-Cashflow:
$-317.54M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$12.60
Fibrogen Inc Stock (FGEN) Company Profile
Firmenname
Fibrogen Inc
Sektor
Branche
Telefon
415-978-1200
Adresse
350 BAY STREET, SAN FRANCISCO, CA
Compare FGEN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
0.00 | 39.28M | 147.75M | -284.23M | -317.54M | -2.93 |
VRTX
Vertex Pharmaceuticals Inc
|
433.07 | 110.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
737.71 | 77.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
691.40 | 42.91B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
317.36 | 42.09B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
283.03 | 31.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-06-26 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-06-26 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-06-26 | Herabstufung | Stifel | Buy → Hold |
| 2023-06-26 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-06-02 | Hochstufung | Stifel | Hold → Buy |
| 2023-01-31 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-01-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-09-22 | Herabstufung | Goldman | Neutral → Sell |
| 2021-08-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-07-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-07-16 | Herabstufung | Stifel | Buy → Hold |
| 2021-04-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-07 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-03-31 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-03-02 | Herabstufung | Jefferies | Buy → Hold |
| 2021-02-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-10-26 | Eingeleitet | Raymond James | Underperform |
| 2020-07-10 | Fortgesetzt | Stifel | Buy |
| 2020-05-01 | Eingeleitet | Cowen | Market Perform |
| 2020-04-27 | Eingeleitet | BofA/Merrill | Neutral |
| 2019-05-29 | Fortgesetzt | Goldman | Neutral |
| 2019-05-10 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Neutral |
| 2019-02-11 | Fortgesetzt | Stifel | Buy |
| 2018-12-19 | Hochstufung | Citigroup | Neutral → Buy |
| 2017-08-08 | Bestätigt | Leerink Partners | Outperform |
| 2017-08-08 | Bestätigt | Stifel | Buy |
| 2017-07-21 | Herabstufung | Goldman | Buy → Neutral |
| 2017-07-11 | Eingeleitet | Jefferies | Buy |
| 2016-02-11 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2016-01-21 | Eingeleitet | Credit Suisse | Neutral |
| 2015-12-04 | Eingeleitet | Citigroup | Buy |
| 2015-09-23 | Eingeleitet | Lake Street | Hold |
| 2015-07-29 | Eingeleitet | Citigroup | Buy |
| 2015-07-20 | Hochstufung | Goldman | Neutral → Buy |
| 2014-12-09 | Eingeleitet | Stifel | Buy |
Alle ansehen
Fibrogen Inc Aktie (FGEN) Neueste Nachrichten
Kyntra Bio (MEX:KYNB) PB Ratio : (As of Mar. 28, 2026) - GuruFocus
Aug Macro: Can FibroGen Inc sustain its profitability2026 Intraday Action & Trade Opportunity Analysis Reports - baoquankhu1.vn
Rate Cut: What is the long term forecast for FibroGen Inc stock2026 PostEarnings & Weekly Breakout Watchlists - baoquankhu1.vn
FibroGen Inc stock leads biotech gains on China asset sale and FDA update amid Q4 earnings scrutiny - AD HOC NEWS
FibroGen Inc stock faces renewed scrutiny amid expanding interstitial lung disease pipeline competit - AD HOC NEWS
Akebia Therapeutics, Inc. v. FibroGen, Inc. - Law.com
FibroGen Inc stock faces scrutiny ahead of delayed Q4 earnings release amid pipeline pressures - AD HOC NEWS
Revenue of Fibrogen from 2020 to 2024 - Statista
Breakout Watch: Is FibroGen Inc stock a value trapPortfolio Update Report & Smart Investment Allocation Insights - baoquankhu1.vn
KYNB: Cash runway extended to 2028 as FG-3246 and roxadustat advance in key late-stage trials - TradingView
Kyntra Bio (KYNB) Fourth Quarter 2025 Earnings Conference Call Transcript - Bitget
Kyntra Bio (KYNB) Q4 2025 Earnings Call Transcript - The Globe and Mail
Kyntra Bio: Q4 Earnings Snapshot - marketscreener.com
Kyntra Bio (NASDAQ: KYNB) pivots to oncology and advances FG-3246, roxadustat - Stock Titan
Kyntra Bio (Nasdaq: KYNB) unveils 2025 results, FG-3246 and roxadustat plans - Stock Titan
New prostate cancer drug trial advances as Kyntra Bio cuts 2025 loss - Stock Titan
FibroGen Q4 2025 earnings preview - MSN
FibroGen (KYNB) Set to Announce Q4 Earnings with Significant Dec - GuruFocus
Bull Run: What is the long term forecast for FibroGen Inc stock2026 Intraday Action & Fast Moving Stock Trade Plans - baoquankhu1.vn
Kyntra Bio (KYNB) CEO reports 277-share tax withholding event - Stock Titan
Tax withholding slightly trims Kyntra Bio (KYNB) CFO share holdings - Stock Titan
Gains Report: Is FibroGen Inc stock a value trap2025 Market WrapUp & Long Hold Capital Preservation Plans - baoquankhu1.vn
Fibrogen Gets Regulator’s Green Light To Sell China Unit To AstraZeneca - MSN
Quarterly Earnings: What is the target price for FibroGen Inc stockJobs Report & Safe Capital Investment Plans - baoquankhu1.vn
FGEN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aug Breakouts: Can FibroGen Inc be the next market leaderJuly 2025 Spike Watch & Safe Capital Preservation Plans - baoquankhu1.vn
What's Going On With Kyntra Bio Stock Tuesday? - Bitget
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 - marketscreener.com
Earnings Risk: Is FibroGen Inc stock a value trapWeekly Stock Recap & Reliable Volume Spike Alerts - baoquankhu1.vn
FibroGen (FGEN) Delisted: What’s Really Left for Shareholders? - AD HOC NEWS
Analyst Upgrade: Why is FibroGen Inc stock going up2025 Performance Recap & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Kyntra Bio to Participate in Upcoming Investor Conferences - The Manila Times
Sentiment Recap: Is FibroGen Inc stock heavily shorted2025 Historical Comparison & Weekly Watchlist of Top Performers - baoquankhu1.vn
Support Test: Will FibroGen Inc. benefit from rising consumer demandPortfolio Gains Summary & High Accuracy Buy Signal Tips - mfd.ru
Can FibroGen Inc. sustain its profitabilityEarnings Trend Report & Reliable Price Breakout Alerts - mfd.ru
Aug Volume: Will Global Indemnity Group LLC Preferred Security benefit from geopolitical trendsVolume Spike & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Is FibroGen Inc. stock a top pick in earnings seasonLong Setup & Daily Technical Forecast Reports - mfd.ru
Jobs Data: Is FibroGen Inc stock a buy or sellEarnings Summary Report & Accurate Trade Setup Notifications - baoquankhu1.vn
KYNB SEC FilingsKYNTRA BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Movers: Will FibroGen Inc benefit from AI trends2025 Top Gainers & Expert-Curated Trade Recommendations - baoquankhu1.vn
Sentiment Review: Will FibroGen Inc benefit from AI trendsWeekly Market Report & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Quarterly Risk: Will FibroGen Inc benefit from AI trends2025 Retail Activity & Smart Allocation Stock Tips - baoquankhu1.vn
Price Action: Can FibroGen Inc be the next market leader2025 Trading Volume Trends & Fast Gain Swing Alerts - baoquankhu1.vn
Kyntra Bio (KYNB) Stock Price, News & Analysis - MarketBeat
Aug Technicals: Will FibroGen Inc stock benefit from M AWeekly Market Outlook & Community Trade Idea Sharing - baoquankhu1.vn
Jobs Data: Will FibroGen Inc. stock outperform international peers2025 Winners & Losers & Safe Capital Growth Tips - Bộ Nội Vụ
Sentiment Review: Will FibroGen Inc benefit from government policyMarket Trend Report & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Aug Sentiment: Is FibroGen Inc. stock heavily shorted2025 Market Outlook & Weekly Watchlist of Top Performers - baoquankhu1.vn
RSI Check: Why FibroGen Inc stock remains on buy listsShort Setup & Reliable Intraday Trade Alerts - Bộ Nội Vụ
How FibroGen Inc. stock reacts to inflationary pressuresJuly 2025 Drop Watch & Risk Managed Investment Signals - Улправда
Kyntra Bio, Inc.: Target Price Consensus and Analysts Recommendations | KYNB | US31572Q8814 - marketscreener.com
Finanzdaten der Fibrogen Inc-Aktie (FGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.03%
2.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):